Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
Clinical trial NCT03420222 · TERMINATED
Trial details
- NCT number
- NCT03420222
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-18
- Primary completion
- 2018-12-28
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.